摘要
目的探讨对经皮冠状动脉介入治疗急性心肌梗死手术期使用比伐卢定的安全性和有效性。方法收集邢台市第三医院2014年1月至2016年6月的急性心肌梗死(AMI)拟行经皮冠状动脉介入(PCI)的病人217例为研究对象,随机数字表法分为观察组(比伐卢定组)和对照组(肝素组),统计分析其安全性和有效性。结果观察组病死率4例(4. 30%)明显低于对照组17例(13. 71%)(χ2=4. 452,P=0. 020);观察组的主要心脏不良事件发生率、大出血发生率、输血发生率、血小板减少发生率均明显低于对照组,差异有统计学意义(P <0. 05);但支架内血栓发生率两组差异无统计学意义(P> 0. 05)。结论与肝素相比,AMI病人行PCI手术期使用比伐卢定,能够获得更好的抗凝疗效,并且还能显著减少血小板减少发生率,具有相对较好的安全性和抗栓疗效。
Objective To investigate the safety and efficacy of Bivalirudin in patients with acute myocardial infarction(AMI)undergoing percutaneous coronary intervention(PCI).Methods 217 cases of AMI patients treated in Xingtai Third Hospital from January 2014 to June 2016 were selected and divided into the observation group(bivalirudin group)and the control group(heparin group)according to the random table method.Then the safety and efficacy of two groups were compared through statistical analysis.Results The incidence of major adverse cardiac events,mortality,major bleeding rate,blood transfusion rate was lower in the control group than that of control group(P<0.05).Furthermore,the control group had a significantly higher incidence rate of thrombocytopenia than that of the observation group[4(4.30%)vs.17(13.71%),χ^2=4.452,P=0.020],while no statistic difference was found in the incidence rate of stent thrombosis(P>0.05).Conclusions Compared with the application of heparin,Bivalirudin has relatively good safety and antithrombotic effect for AMI patients undergoing PCI,which can also significantly reduce the incidence of thrombocytopenia.
作者
穆金兴
陈要起
齐丽平
陈洪波
MU Jinxing;CHEN Yaoqi;QI Liping;CHEN Hongbo(Xingtai Third Hospital Cardiology,Xingtai,Hebei054000,China)
出处
《安徽医药》
CAS
2019年第1期158-160,共3页
Anhui Medical and Pharmaceutical Journal
